Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast06
jRCT2061200028Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in breast cancer (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-free survival by blinded independent central review in the hormone receptor-positive HER2-low population. Started Dec 2020; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2061200028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061200028.